Study Release: Recent social media chatter centers on three new peer-reviewed studies highlighting the clinical value of Bionano Genomics' optical genome mapping technology in diagnosing myelodysplastic syndromes and acute myeloid leukemia. Analysts note these findings could bolster the company's position in precision medicine.
Market Reaction: Traders on social media express optimism as shares climbed around 11 percent following the announcements. Discussions emphasize the potential for expanded adoption in clinical settings amid ongoing revenue growth projections.
Broader Context: Community sentiment remains focused on the data's implications for long-term innovation in genomic analysis. Participants highlight how such advancements differentiate the firm in a competitive biotech landscape.
Note: This discussion summary was generated from an AI condensation of post data.
Bionano Genomics Insider Trading Activity
Bionano Genomics insiders have traded $BNGO stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BNGO stock by insiders over the last 6 months:
- ALBERT LUDERER (Interim Chief Executive) has made 2 purchases buying 8,000 shares for an estimated $9,704 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Bionano Genomics Revenue
Bionano Genomics had revenues of $-6.7M in Q2 2026. This is a decrease of -199.1% from the same period in the prior year.
You can track BNGO financials on Quiver Quantitative's BNGO stock page.
You can access data on BNGO stock through the Quiver Quantitative API.
Bionano Genomics Hedge Fund Activity
We have seen 19 institutional investors add shares of Bionano Genomics stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GSA CAPITAL PARTNERS LLP removed 187,493 shares (-55.5%) from their portfolio in Q2 2026, for an estimated $211,867
- DRW SECURITIES, LLC removed 168,453 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $197,090
- GEODE CAPITAL MANAGEMENT, LLC removed 77,540 shares (-46.3%) from their portfolio in Q2 2026, for an estimated $87,620
- CARRET ASSET MANAGEMENT, LLC added 55,000 shares (+78.6%) to their portfolio in Q2 2026, for an estimated $62,149
- TWO SIGMA INVESTMENTS, LP removed 40,513 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $47,400
- JANE STREET GROUP, LLC added 35,728 shares (+inf%) to their portfolio in Q2 2026, for an estimated $40,372
- TWO SIGMA SECURITIES, LLC removed 18,056 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $20,403
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Bionano Genomics Government Contracts
We have seen $43,124 of award payments to $BNGO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
